DataString Consulting Company Logo
DataString Consulting Company Logo
Macitentan Market
Home»Recent Reports»Macitentan Market

Macitentan Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802328, Published - May 2025

Segmented in Delivery Methods (Oral Administration, Intravenous Infusion), Therapeutic Applications (Pulmonary Arterial Hypertension, Connective Tissue Disease-PAH, Congenital Heart Disease-PAH, Others), Target Audience and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Macitentan Market Outlook

The market, for Macitentan was estimated at $618.4 million in 2024; and it is anticipated to increase to $943.8 million by 2030 with projections indicating a growth to around $1.3 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.3% over the forecast period. The significant rise in the Macitentan markets growth can be linked to key factors at play here. One of the reasons is the increasing worldwide occurrence of Pulmonary Arterial Hypertension (PA H) which holds a pivotal position in this scenario. Moreover the growing need for Macitentan. An endothelin receptor antagonist predominantly employed in treating PA H. Highlights its importance. Progressive developments in the management of PA H have also heightened Macitentans significance in the realm of healthcare. This underscores its role, in combating this challenging condition effectively.


Macitentan is well known for its effectiveness in decreasing illness and death rates in patients with PAH ​​(pulmonary arterial hypertension) placing it ahead of other similar medications on the market. The unique ability of this treatment to block endothelin receptors and enhance heart function while extending life expectancy has made it a valuable component of guidelines for treating PAHand enhancing its potential in other medical fields such, as oncology highlights the diverse power and versatility of this medication.


Market Size Forecast & Key Insights

2019
$618M2024
2029
$1.3B2034

Absolute Growth Opportunity = $633M

The Macitentan market is projected to grow from $618.4 million in 2024 to $1.25 billion in 2034. This represents a CAGR of 7.3%, reflecting rising demand across Pulmonary Arterial Hypertension Treatment, Diagnostics Tool and Cardiovascular Therapy.

The Macitentan market is set to add $633 million between 2024 and 2034, with manufacturer targeting Connective Tissue Disease-PAH & Congenital Heart Disease-PAH Therapeutic Applications projected to gain a larger market share.

With Rising incidence of pulmonary arterial hypertension , and Increasing pharmaceutical r&d activities, Macitentan market to expand 102% between 2024 and 2034.

Opportunities in the Macitentan Market

Technological Innovations for Advanced Drug Delivery

The collaboration between pharmaceutical companies and technology firms has the potential to lead to drug delivery methods, for Macitentan enabling the creation of advanced medication distribution systems that improve patient adherence and treatment outcomes.

Leveraging Untapped Segments and Focusing on Evolving Consumer Needs in Emerging Markets

Macitentan shows promise for growth in medical fields beyond its current use in treating pulmonary arterial hypertension . Exploring the treatments effectiveness for uncommon lung diseases could open up new opportunities for Macitentan to reach a broader audience, in the market.

By identifying up and coming markets as sources of growth potentiality for Macitentan they can leverage the developing healthcare systems and increasing consumer knowledge about PAE to their advantage. Countries such as India China and Brazil offer possibilities for the advancement of Macitentan, in the market.

Growth Opportunities in North America and Europe

Europe Outlook

The Macitentan market shows promising growth opportunities due to the increasing number of diseases requiring advanced treatments in the region. The presence of healthcare facilities and substantial investments in healthcare contribute to the business prospects of Macitentan in this region. Competition is intense in the region due to changes in the drug market after the expiration of key drug patents. Moreover the growing awareness about enhancing the quality of life for patients plays a role in encouraging more widespread use of drugs like Macitentan in everyday medical practices, across Europe.

North America Outlook

In North America's healthcare landscape and research institutions are delving deeply into exploring the benefits of Macitentan drug treatment for Pulmonary Arterial Hypertension . The market is expanding due to robust regulatory measures improving drug approvals and ongoing clinical trials focused specificallyon PAH therapies. In this environment major players in the market are heavily investing in collaborations and cutting edge research to strengthen their position, in the industry. The region also experiences a frequency of related conditions which has led to an increased need for effective treatments such as Macitentan, for pulmonary arterial hypertension consequently fueling the expansion of the market.

North America Outlook

In North America's healthcare landscape and research institutions are delving deeply into exploring the benefits of Macitentan drug treatment for Pulmonary Arterial Hypertension . The market is expanding due to robust regulatory measures improving drug approvals and ongoing clinical trials focused specificallyon PAH therapies. In this environment major players in the market are heavily investing in collaborations and cutting edge research to strengthen their position, in the industry. The region also experiences a frequency of related conditions which has led to an increased need for effective treatments such as Macitentan, for pulmonary arterial hypertension consequently fueling the expansion of the market.

Europe Outlook

The Macitentan market shows promising growth opportunities due to the increasing number of diseases requiring advanced treatments in the region. The presence of healthcare facilities and substantial investments in healthcare contribute to the business prospects of Macitentan in this region. Competition is intense in the region due to changes in the drug market after the expiration of key drug patents. Moreover the growing awareness about enhancing the quality of life for patients plays a role in encouraging more widespread use of drugs like Macitentan in everyday medical practices, across Europe.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, China, Japan, UK are expected to grow at 4.7% to 7.0% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 8.4% to 10.1% CAGR

Market Analysis Chart

The pharmaceutical industry is highly competitive with a demand for Macitentan driven by its effectiveness in treating pulmonary arterial hypertension . This unique endothelin receptor antagonist has made an impact due to its innovative approach to treating PAF and has gained popularity among healthcare providers and patients alike despite facing some challenges, in the market.

Recent Developments and Technological Advancement

December 2024

Actelions Pharmaceuticals unveiled an upgraded version of Macitentan that provides improved dosage management options. This update aims to offer flexibility, for doctors and enhance treatment customization for patients.

October 2024

On World Pulmonary Hypertension Day Pfizer Inc ramped up Macitentan production to keep up with the increasing demand.

July 2024

Johnson & Johnson has disclosed a long term partnership, with Eli Lilly to investigate uses of Macitentan in the realm of personalized medicine.

there has been a growing interest in Macitentan among pharmaceutical experts due to its effectiveness, in treating pulmonary arterial hypertension as a versatile endothelin receptor antagonist.

Impact of Industry Transitions on the Macitentan Market

As a core segment of the Pharmaceutical industry, the Macitentan market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Personalized Medicine and Advancements in Drug Delivery Systems have redefined priorities across the Pharmaceutical sector, influencing how the Macitentan market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence of Personalized Medicine:

The field of medicine has been experiencing changes due to the rise of personalized treatments like Macitentan in managing Pulmonary Arterial Hypertension . Through advancements in genomics and proteomics techniques healthcare professionals have enhanced the effectiveness of Macitentan therapy leading to results for patients and increased drug efficiency. This shift has driven up the demand for Macitentan. Solidified its reputation as an effective solution, in managing PAHP.

2

Advancements in Drug Delivery Systems:

The field has also seen progress in drug delivery systems that have enhanced the effectiveness of drugs such as Macitentan. Innovative delivery techniques have minimized side effects and made it easier for patients to follow their treatment plans by simplifying the way medication is taken. A clear example of this progress is the change in how Macitentan is administered. Moving from oral methods to modified release systems. This shift has led to an improvement in how patients feel during treatment and their overall outcomes solidifying Macitentans position, in the field.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Macitentan market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising incidence of Pulmonary Arterial Hypertension , and Conducive Reimbursement Policies

The worldwide occurrence of arterial hypertension a severe medical condition that poses a threat to life is also believed to be on the rise every year which necessitates the need for efficient PAOH treatment approaches and drugs such, as Macitentan. An agent that acts on endothelin receptors and is also employed in the management of PAOH. Thereby contributing to the expansion of the market.
Internationally governments and health institutions are also recognizing the seriousness of PAHa syndrome. Are also implementing beneficial reimbursement regulations as a result of this awareness. This ensures that Macitentan treatment for PAHa becomes more financially accessible reinforcing its role in driving the increasing demand, in the market. These regulations have also the potential to greatly enhance results enabling further expansion of the Macitentan market.
The growth of research and development efforts in companies is also driving the expansion of the Macitentan market as technology advancements, in drug development allow laboratories to explore and create more effective medications that contribute to the positive growth of the Macitentan market.

Restraint: Stringent Regulatory Guidelines

Being a product like Macitentan faces strict regulations in every market it enters due to its use in treating pulmonary arterial hypertension. The rules and guidelines regarding the production and distribution of Macitentan are closely. Enforced to ensure patient safety and well being. Non compliance can result in fines, retrieval of the product from the market or even a ban which directly affects patient health. Any alterations in the landscape can have a notable impact, on the market dynamics of Macitentan.

Challenge: High Cost of Treatment

Treatment with Macitentan is notorious for being expensive; in less affluent regions, like developing and underdeveloped nations where patients buying power may not only match up to the high costs involved in this therapy. This disparity impacts market demand directly. Hampers the growth potential of the market.

Supply Chain Landscape

Raw Material Acquisition

Johnson Matthey

Cambrex Corporation

API Formation

Actelion Pharmaceuticals

Janssen Biotech

Product Manufacturing
Johnson & Johnson / Novartis
End Use
PAH treatment / Systemic Sclerosis treatment
Raw Material Acquisition

Johnson Matthey

Cambrex Corporation

API Formation

Actelion Pharmaceuticals

Janssen Biotech

Product Manufacturing

Johnson & Johnson

Novartis

End Use

PAH treatment

Systemic Sclerosis treatment

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Pulmonary Arterial Hypertension Treatment
Pharmaceuticals
Actelion Pharmaceuticals Ltd
Focused on clinical trials and global market distribution
Systemic Sclerosis Therapy
Pharmaceuticals
Johnson & Johnson
Investment in innovative product development and market expansion
Digital Ulcers Treatment
Pharmaceuticals
Novartis AG
Leverage scientific advancements and robust pipeline growth

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Macitentan market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Macitentan in Diagnostics Tool, Cardiovascular Therapy and Pulmonary Arterial Hypertension Treatment

Diagnostics Tool

In, today's healthcare field Macitentan is being utilized as an aid. The injectable form is preferred for its absorption rate.

Cardiovascular Therapy

Macitentan is considered one of the vasodilators worldwide and is commonly used to treat cardiovascular conditions due to its effectiveness and easy oral administration method preferred by many patients. This medication helps in decreasing hypertrophy and fibrosis in the heart muscles while also leading to hospital visits and better outcomes for patients. Big pharmaceutical companies like Pfizer and AstraZeneca have shown interest in this medication due to its high efficacy rates, with AstraZeneca specifically leading the market in this regard.

Pulmonary Arterial Hypertension Treatment

Macitentan is well known worldwide for its effectiveness in treating Pulmonary Arterial Hypertension . The oral form of Macitentan is commonly used to reduce discomfort by decreasing blood pressure in the pulmonary arteries through the blocking of endothelin receptors 1. This application stands out for its long lasting impact and is a preferred choice among major players such, as Janssen Pharmaceuticals and Actelion Pharmaceuticals. The latter having a strong market reputation fueled by Opsumit, a macitentan based drug that leads the market.

Macitentan vs. Substitutes:
Performance and Positioning Analysis

Macitentan outshines its alternatives with more prolonged efficacy and fewer side effects. Its unique market position stems from its potential for treating life-threatening pulmonary arterial hypertension . With rising PAH cases, the demand for Macitentan is set to surge

Macitentan
  • Bosentan /
  • Ambrisentan /
  • riociguat tablets
    Proven effectiveness in treating pulmonary arterial hypertension, Favorable safety profile
    Potential for liver damage, strict need for regular monitoring of liver function
    Elevated efficacy in controlling pulmonary arterial hypertension, significant reduction in the risk of morbidity and mortality among patients
    potential for serious side effects such as hepatic injury

Macitentan vs. Substitutes:
Performance and Positioning Analysis

Macitentan

  • Proven effectiveness in treating pulmonary arterial hypertension, Favorable safety profile
  • Potential for liver damage, strict need for regular monitoring of liver function

Bosentan / Ambrisentan / riociguat tablets

  • Elevated efficacy in controlling pulmonary arterial hypertension, significant reduction in the risk of morbidity and mortality among patients
  • potential for serious side effects such as hepatic injury

Macitentan outshines its alternatives with more prolonged efficacy and fewer side effects. Its unique market position stems from its potential for treating life-threatening pulmonary arterial hypertension . With rising PAH cases, the demand for Macitentan is set to surge

Loading...

Research Methodology

This market research methodology defines the Macitentan market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Macitentan across Pulmonary Arterial Hypertension, Connective Tissue Disease-PAH, and Congenital Heart Disease-PAH Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Actelion Pharmaceuticals Ltd, Johnson & Johnson, and Zydus Cadila by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Acquisition, API Formation, and Product Manufacturing. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Macitentan segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Acquisition (Johnson Matthey, Cambrex Corporation), API Formation (Actelion Pharmaceuticals, Janssen Biotech), and Product Manufacturing. Our parallel substitute analysis examines Bosentan, Ambrisentan, and riociguat tablets, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Actelion Pharmaceuticals Ltd, Johnson & Johnson, and Zydus Cadila, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Macitentan market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Macitentan Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 663 million
Revenue Forecast in 2034USD 1.25 billion
Growth RateCAGR of 7.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024618 million
Growth OpportunityUSD 633 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024618 million USD
Market Size 2027764 million USD
Market Size 2029879 million USD
Market Size 2030943 million USD
Market Size 20341.25 billion USD
Market Size 20351.34 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDelivery Methods, Therapeutic Applications, Target Audience
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledActelion Pharmaceuticals Ltd, Johnson & Johnson, Zydus Cadila, MSN Laboratories, Hetero Drugs, GLENMARK PHARMACEUTICALS, Sandoz, Mylan N.V., Cipla Ltd, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd and Alembic Pharmaceuticals Ltd
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Macitentan Market Size, Opportunities & Strategic Insights, by Delivery Methods

4.1Oral Administration
4.2Intravenous Infusion
Chapter 5

Macitentan Market Size, Opportunities & Strategic Insights, by Therapeutic Applications

5.1Pulmonary Arterial Hypertension
5.2Connective Tissue Disease-PAH
5.3Congenital Heart Disease-PAH
5.4Others
Chapter 6

Macitentan Market Size, Opportunities & Strategic Insights, by Target Audience

6.1Medical Practitioners
6.2Research Institutions
6.3Pharmaceutical Distributors
Chapter 7

Macitentan Market, by Region

7.1North America Macitentan Market Size, Opportunities, Key Trends & Strategic Insights
7.1.1U.S.
7.1.2Canada
7.2Europe Macitentan Market Size, Opportunities, Key Trends & Strategic Insights
7.2.1Germany
7.2.2France
7.2.3UK
7.2.4Italy
7.2.5The Netherlands
7.2.6Rest of EU
7.3Asia Pacific Macitentan Market Size, Opportunities, Key Trends & Strategic Insights
7.3.1China
7.3.2Japan
7.3.3South Korea
7.3.4India
7.3.5Australia
7.3.6Thailand
7.3.7Rest of APAC
7.4Middle East & Africa Macitentan Market Size, Opportunities, Key Trends & Strategic Insights
7.4.1Saudi Arabia
7.4.2United Arab Emirates
7.4.3South Africa
7.4.4Rest of MEA
7.5Latin America Macitentan Market Size, Opportunities, Key Trends & Strategic Insights
7.5.1Brazil
7.5.2Mexico
7.5.3Rest of LA
7.6CIS Macitentan Market Size, Opportunities, Key Trends & Strategic Insights
7.6.1Russia
7.6.2Rest of CIS
Chapter 8

Competitive Landscape

8.1Competitive Dashboard & Market Share Analysis
8.2Company Profiles (Overview, Financials, Developments, SWOT)
8.2.1Actelion Pharmaceuticals Ltd
8.2.2Johnson & Johnson
8.2.3Zydus Cadila
8.2.4MSN Laboratories
8.2.5Hetero Drugs
8.2.6GLENMARK PHARMACEUTICALS
8.2.7Sandoz
8.2.8Mylan N.V.
8.2.9Cipla Ltd
8.2.10Teva Pharmaceutical Industries Ltd
8.2.11Sun Pharmaceutical Industries Ltd
8.2.12Alembic Pharmaceuticals Ltd